— Company to Host Conference Call on
— Data on Aripiprazole Lauroxil for Treatment of Schizophrenia and ALKS 5461 for Treatment of Major Depressive Disorder Will Also be Presented at Meeting —
ALKS 3831
-
Oral presentation, “ALKS 3831: A Novel Drug Candidate for the
Treatment of Schizophrenia,” will be presented during the
Pharmaceutical Pipeline symposium on
Monday, June 22, 2015 ,2:00 p.m. –4:00 p.m. EDT . -
Poster #T6, “ALKS 3831: A Novel Drug Candidate for the Treatment of
Schizophrenia,” will be available during Poster Session I,
Tuesday, June 23, 2015 ,11:15 a.m. –1:00 p.m. EDT . -
Oral presentation, “A Phase 2, Randomized, Olanzapine-Controlled Study
of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults with
Schizophrenia,” will be presented on
Tuesday, June 23, 2015 ,3:30 p.m. –4:30 p.m. EDT .
Aripiprazole Lauroxil
-
Poster #T88, “Effect of Aripiprazole Lauroxil on Metabolic and
Endocrine Profiles, and Related Safety Considerations in Acute
Schizophrenia,” will be available during Poster Session I,
Tuesday, June 23, 2015 ,11:15 a.m. –1:00 p.m. EDT . -
Oral presentation, “Efficacy and Safety of Aripiprazole Lauroxil in
Acute Exacerbation of Schizophrenia: Results from a Double-Blind
Placebo-Controlled Study,” will be presented on
Tuesday, June 23, 2015 ,3:30 p.m. –4:30 p.m. EDT . -
Poster #W88, “Effect of Aripiprazole Lauroxil on Personal and Social
Functioning and Health-Related Quality of Life Among Patients with
Schizophrenia,” will be available during Poster Session II,
Wednesday, June 24, 2015 ,12:00 p.m. –2:00 p.m. EDT .
ALKS 5461
-
Oral presentation “ALKS 5461 as Adjunctive Treatment of Major
Depressive Disorder: Phase 3, Randomized, Double-Blind Study
(FORWARD-1) Evaluating Two Titration Schedules,” will be presented on
Tuesday, June 23, 2015 ,3:30 p.m. –4:30 p.m. EDT . -
Poster #W36, “Combinations of Buprenorphine and Samidorphan Modulate
Glutamate and GABA Transmission in the Medial Prefrontal Cortex and
Ventral Hippocampus of Male Wistar Rats,” will be available during
Poster Session II,
Wednesday, June 24, 2015 ,12:00 p.m. –2:00 p.m. EDT .
A full list of all presentations at the ASCP meeting is available at: http://ascpmeeting.org/.
Conference Call
About ALKS 3831
ALKS 3831 is a
proprietary, investigational medicine designed as a broad-spectrum
antipsychotic for the treatment of schizophrenia. ALKS 3831 is composed
of samidorphan, a novel, potent mu-opioid antagonist, in combination
with the established antipsychotic drug, olanzapine. ALKS 3831 is
designed to attenuate olanzapine-induced metabolic side effects,
including weight gain, in patients with schizophrenia and to have
utility in the treatment of schizophrenia in patients with alcohol use.
About Aripiprazole Lauroxil
Aripiprazole
lauroxil is an injectable atypical antipsychotic with one-month and
extended-duration formulations in development for the treatment of
schizophrenia. Once in the body, aripiprazole lauroxil converts to
aripiprazole, which is commercially available under the name ABILIFY®.
As a long-acting investigational medication based on Alkermes’
proprietary LinkeRx® technology, aripiprazole lauroxil is
designed to have multiple dosing options and to be administered in a
ready-to-use, pre-filled product format.
About ALKS 5461
ALKS 5461 is a
proprietary, oral investigational medicine for the treatment of major
depressive disorder (MDD). ALKS 5461 acts as a balanced neuromodulator
in the brain and represents a new approach with a novel mechanism of
action for treating MDD. In
About Alkermes
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, but not limited to,
statements concerning the therapeutic value of our investigational
product candidates. The company cautions that forward-looking statements
are inherently uncertain. Although the company believes that such
statements are based on reasonable assumptions within the bounds of its
knowledge of its business and operations, the forward-looking statements
are neither promises nor guarantees and they are necessarily subject to
a high degree of uncertainty and risk. Actual performance and results
may differ materially from those expressed or implied in the
forward-looking statements due to various risks and uncertainties. These
risks and uncertainties include those risks described in the
LinkeRx® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005339/en/
Source:
Alkermes
For Investors:
Rebecca
Peterson, +1-781-609-6378
or
For Media:
Jennifer Snyder,
+1-781-609-6166